Bright Minds Biosciences Inc. (CNSX: DRUG)
Health Care · Biotechnology · US
CA$73.52
+4.15% today · -0.6% 1Y
Bright Minds Biosciences Inc. (CNSX: DRUG) operates in the Biotechnology industry within the Health Care sector. The company is valued at $488.45M and employs 26 people.
Over the last twelve months the share price has lost 0.6%, trading between 69.20 and 170.00.
Tweenvest scores Bright Minds Biosciences Inc. across four factors: quality 38/100, value 53/100. Its strongest factor is value.
DRUG price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $488.45M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.86
- Dividend yield
- —
- Beta (5Y)
- 0.23
- 52-week high
- CA$170.00
- 52-week low
- CA$69.20
- Avg volume (3M)
- —
- Shares outstanding
- 9.86M
- Employees
- 26
- Next earnings
- —
About Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
- ISIN
- CA10919W4056
- Founded
- 2017
- Listed since
- Feb 9, 2021
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Entera Bio Ltd.NasdaqCM: ENTX | $495.19M | $2.50 | -12.59% |
| Allogene Therapeutics, Inc.NasdaqGS: ALLO | $494.05M | $1.40 | -2.10% |
| Beijing Leadman Biochemistry Co.,Ltd.SZSE: 300289 | $491.47M | CN¥6.06 | +2.02% |
| Guanhao Biotech Co.,Ltd.SZSE: 300238 | $489.37M | CN¥11.95 | -0.33% |
| ACRO Biomedical Co., Ltd.TPEX: 6748 | $486.06M | NT$216.00 | -5.26% |
| Qyuns Therapeutics Co., Ltd.SEHK: 2509 | $483.91M | HK$17.00 | +1.37% |
| Autolus Therapeutics plcNasdaqGS: AUTL | $481.75M | $1.77 | -2.21% |
| Blau Farmacêutica S.A.BOVESPA: BLAU3 | $477.46M | R$10.82 | +5.87% |
Figures last refreshed Oct 4, 2026.